pbt - an investment view (imo), page-12

I share your pain Pixie.

I still fee positive though.

I spoke to the company's investor relations today. They Re-enforced what was said on the conference call. I asked that he relay the message to the board about the well being of the shareholders.

I asked if they will look at other areas in the extension trials (ie cognition/executive function)...he said he couldn't comment on that, and that they will be updating the market soon. They are working through the data analysis.

He said they are still progressing with PBT2 for AD & HD. He said Prana is not a one trick pony. Heaps in the pipeline.

I asked if the recent imagine results will impact the HD trial progression and the push for orphan drug status...there is no impact.

I don't think HD phase 3 and orphan drug status is priced into the current price.

We have been patient, just need to hold on a little longer guys.

Best of luck to all.